Natera (NASDAQ:NTRA) Sets New 52-Week High at $124.83

Natera, Inc. (NASDAQ:NTRA) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $124.83 and last traded at $124.76, with a volume of 824727 shares. The stock had previously closed at $118.73.

Analysts Set New Price Targets

NTRA has been the subject of several analyst reports. Piper Sandler lifted their price objective on shares of Natera from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. BTIG Research boosted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stephens reissued an “overweight” rating and set a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Morgan Stanley boosted their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, UBS Group lowered their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $120.07.

Natera Price Performance

The stock has a market cap of $15.32 billion, a price-to-earnings ratio of -38.05 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock’s 50 day simple moving average is $111.94 and its two-hundred day simple moving average is $103.12.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the prior year, the business posted ($0.97) earnings per share. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. On average, analysts forecast that Natera, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the transaction, the insider now directly owns 206,400 shares of the company’s stock, valued at $21,211,728. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Daniel Rabinowitz sold 1,057 shares of the firm’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $109.66, for a total value of $296,082.00. Following the sale, the insider now owns 304,508 shares in the company, valued at approximately $33,392,347.28. The disclosure for this sale can be found here. Insiders have sold 92,388 shares of company stock worth $10,205,064 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NTRA. International Assets Investment Management LLC lifted its holdings in Natera by 6,007.5% in the fourth quarter. International Assets Investment Management LLC now owns 7,329 shares of the medical research company’s stock valued at $459,000 after buying an additional 7,209 shares during the period. Victory Capital Management Inc. boosted its position in shares of Natera by 13.9% in the 4th quarter. Victory Capital Management Inc. now owns 26,109 shares of the medical research company’s stock worth $1,635,000 after purchasing an additional 3,178 shares during the last quarter. Natixis Advisors L.P. increased its holdings in Natera by 29.9% in the fourth quarter. Natixis Advisors L.P. now owns 19,553 shares of the medical research company’s stock valued at $1,224,000 after purchasing an additional 4,497 shares during the last quarter. M&T Bank Corp lifted its stake in Natera by 11.6% in the fourth quarter. M&T Bank Corp now owns 5,424 shares of the medical research company’s stock valued at $340,000 after buying an additional 565 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Natera by 7.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 997,909 shares of the medical research company’s stock worth $62,509,000 after buying an additional 68,480 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.